PTEN Research’s Post

https://lnkd.in/e2p6SFgk 🚀 Exciting News Alert! 🚀   We're thrilled to announce the launch of the Liver Ring Trial, a groundbreaking collaboration between TissUse GmbH and ESQlabs GmbH (a computational model expert), UCB, a global biopharmaceutical company and initiators of the ring trial, and five other pharmaceuticals (Orion Corporation, Sanofi-Aventis Recherche & Développement, Technologie Servier France/Biologie Servier, AstraZeneca AB, and Boehringer Ingelheim), set to revolutionize drug safety assessment! 👉 Press Release: https://lnkd.in/e2p6SFgk Novel Liver Ring Trial Set to Revolutionize Drug Safety Assessment We're embarking on a mission to validate the reproducibility and accuracy of Liver Micro-Physiological Systems (MPS) in predicting drug-induced liver injury (DILI) and intrinsic clearance. This marks a paradigm shift in non-clinical drug assessment.  To validate a tool to be used for the evaluation of both drug safety and metabolism. "Our microfluidic platform is not just about simulating liver functions; it's about creating a more holistic organ-to-organ interaction, thereby offering a more accurate representation of human physiology," stated Dr. Reyk Horland, CEO at TissUse. With the guidance of regulatory bodies like the European Medicines Agency (EMA) and the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre (JRC), we aim to provide more confidence to use MPS data for regulatory submission and, ultimately, support decision making. Join us in shaping the future of drug safety assessment! #LiverRingTrial #DrugSafety #Innovation #PreclinicalResearch #NAMs #OrganOnChip

[Clinical Trials] VYNE Therapeutics' phase 1b trial of VYN201 shows biological activity and positive effect on key biomarkers in nonsegmental vitiligo https://lnkd.in/gxestuXA Ferrer Internacional's phase 3 trial of FAB122 in amyotrophic lateral sclerosis fails to show significant benefit over placebo in disease progression https://lnkd.in/g5CwBDDw [Deals] Amgen Secures Exclusive Global Rights for Tepezza Subcutaneous Formulation in Xeris Pharmaceuticals Collaboration https://lnkd.in/gN5NaY6h Sermonix Pharmaceuticals Signs Exclusive Collaboration and License Agreement with Henlius Biopharmaceuticals for Lasofoxifene in China, Potentially Reaching $58M Milestone Payment https://lnkd.in/gJGfa2e3 Ji Xing Pharmaceuticals Shanghai Secures Global Development Rights for BIIB131 in Acute Ischemic Stroke Agreement from Biogen https://lnkd.in/gPGBtJHu

The IFOPA is hosting the 6th FOP Drug Development Forum on June 26-28 in Stockholm, Sweden as well as virtually. The DDF features 12-minute talks grouped into five sessions: 1. Clinical Trials in FOP 2. Observational Research and Real-World Evidence 3. Drug Discovery and the ACVR1/ALK2 Receptor 4. Systems Biology Approaches to the Treatment of FOP 5. Untargeted Discovery in FOP Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2023: https://lnkd.in/dfrq8sYC Deadline is February 19. May 10 is the submission deadline for late-breaking data (data published February-May 2024). The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options.

1 Week Until the Deadline: February 19. Apply to present at the FOP Drug Development Forum June 26-28 in Stockholm. Presentations can be made in person or virtually. The DDF features 12-minute "FOP Talks" grouped in sessions that cover learnings from clinical trials, observational research, and rational drug design. This year’s event includes a session on untargeted discovery in FOP. Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2024: https://lnkd.in/dfrq8sYC The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf

Apply to present at the FOP Drug Development Forum (June 26-28 in Stockholm, Sweden as well as virtually). The DDF features 12-minute "FOP Talks" grouped in sessions that cover learnings from clinical trials, observational research, and rational drug design. This year’s event includes a session on untargeted discovery in FOP. Apply to do a platform presentation and/or a poster with unpublished data or data not published before January 1, 2024: https://lnkd.in/dfrq8sYC Deadline is February 19. The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf

We at the Psychedelic Therapeutics & Drug Development Conference are excited to have Ed Christian, Ph.D., Executive Director Clinical Science, Gilgamesh Pharmaceuticals presenting at our 4th annual event, which is taking place in Boston on May 23-24. Dr. Christian will present results of Phase 1 single and multiple dose studies of the Gilgamesh proprietary oral NMDA antagonist, GM-1020, in healthy volunteers. Results have identified a hypothetical clinical dose range where resting EEG and subjective pharmacodynamic scales establish increasing target engagement. Over this dose range, however, minimal dissociative and sedative adverse events were observed, which are well known to be significant and undesirable adverse effects that necessitate clinical supervision during subanesthetic ketamine / esketamine dosing to treat major depression. In this presentation, Dr. Christian will discuss details of the Phase 1 safety, PK and PD results in which they established good dose-proportional PK with high oral bioavailability, and PD effects supporting a range of target engagement across the study regimen. Learn more about this event by visiting https://lnkd.in/eM5iiPn. #psychedelics #psychedelicresearch #psychedelictherapy #boston Christian Gray Laszlo Kiss jonathan sporn

Register for the FOP Drug Development Forum in June in Stockholm, Sweden (or virtually). With the first-ever treatment for FOP approved in select countries and five active FOP clinical trials, there is still an abundance of preclinical research with the potential to be translated into safe and effective new medicines. Molecules advancing drug discovery, advanced therapeutic modalities and new technologies must continually be explored for their potential to treat understudied signs and symptoms of FOP. The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf

Today, Kariya Pharmaceuticals, one of the very first companies BII supported, announced the successful dosing of the first cohort in a Phase 1 first-in-human trial for its lead compound, KP405, that can slow the progression of Parkinson's Disease.💊 According to Ian Laquian, CEO of Kariya Pharmaceuticals, receiving financial support at an early stage has been instrumental in bringing its lead compound one step closer to patients in need.📈   "First-in-human trials are momentous occasions for any organization, but today is extra special when you've been working on a concept for over a decade. There are so many people to thank and recognize on the way to this milestone, but none more important than the Novo Nordisk Foundation and the BioInnovation Institute." Matthias Wulf, Principal at BII, is pleased to see how far Kariya has come since receiving EUR 1.3M in financial support through BII's former Creation House program in 2019.   “It is fantastic to see how Kariya has moved their first-in-class treatment to the clinic to make a difference for people with Parkinson’s disease. It shows what good science and determined founders can achieve when they receive the proper support, he says." A huge congratulations to the Kariya team. We look forward to following your future progress to help people with Parkinson's disease.🚀 Christian Hölscher Bobby Soni Jens Nielsen Trine Bartholdy Sanne Brun Jensen Umar Adegoke Anders Østerby Mønsted Katrine Villarreal Villumsen #biotech #parkinsonsdisease #drugdevelopment #clinicaltrial #pharma #lifescience

▶️🖱️ Now available on-demand! Watch our webinar featured on Scientist.com on the Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases! 👉 Click here to watch: https://buff.ly/3yGYTiT This webinar features our Director of Scientific Engagement, Dr. Jun Wang, and BioRay Pharmaceutical's President, Dr. Gang Chen. Key topics include: ☑️ Advantages of using humanized mouse models to evaluate ADCs ☑️ Applications of humanized mice to evaluate ADCs in autoimmune disease models ☑️ The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM) #adcs #antibodydrugconjugates #autoimmune #mousemodels https://buff.ly/3yGYTiT

If you missed the live webinar, you can now watch the recording! #autoimmunemodels